Neumora Therapeutics, Inc. Quarterly Operating Income (Loss) in USD from Q3 2022 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Neumora Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q3 2022 to Q3 2024.
  • Neumora Therapeutics, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$76.6M, a 34.8% decline year-over-year.
  • Neumora Therapeutics, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$315M.
  • Neumora Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$252M, a 85.5% decline from 2022.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$315M -$76.6M -$19.8M -34.8% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-12
Q2 2024 -$295M -$63.8M -$21.8M -51.7% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-06
Q1 2024 -$273M -$60.1M -$20.9M -53.4% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-07
Q4 2023 -$252M -$114M Oct 1, 2023 Dec 31, 2023 10-K 2024-03-07
Q3 2023 -$56.9M -$26.3M -85.8% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-12
Q2 2023 -$42.1M Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-06
Q1 2023 -$39.2M Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-07
Q3 2022 -$30.6M Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-01
* An asterisk sign (*) next to the value indicates that the value is likely invalid.